News
Author: admin als-handoff
-
Achieve Announces Patent Granted on Novel Formulation of Cytisine
SEATTLE, Wash and VANCOUVER, British Columbia, May 7, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that the UK Intellectual Property Office has granted Achieve a patent (no. 2550241) on cytisine succinate salt. Cytisine is a plant-based…
-
Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health
BOTHELL, Wash. and VANCOUVER, British Columbia, March. 6, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced that the World Conference on Tobacco or Health (WCTOH) will be holding a symposium on cytisine research at this year’s annual conference, March 7-9th in Cape Town, South Africa. The cytisine symposium titled “Is a Globally…
-
Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
BOTHELL, Wash and VANCOUVER, British Columbia, March 1, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today highlighted recent accomplishments and announced fourth quarter and year-end 2017 financial results. Recent Highlights. Announced preliminary results from clinical study evaluating pharmacokinetic…
-
Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
BOTHELL, Washington and VANCOUVER, British Columbia, February 20, 2018 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced preliminary data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisine. The study, initiated in October 2017,…
-
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
BOTHELL, Washington and VANCOUVER, British Columbia, Jan. 24, 2018 /PRNewswire/ — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an amendment to their Technology Licence Agreement with the University of Bristol, United Kingdom. Achieve has been granted exclusive rights for…